MedTrace Logo

Study of Adalimumab in Patients With Axial Spondyloarthritis

NCT00939003 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2014-09-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate how well adalimumab works in the short and long term in patients with axial spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.

Conditions

  • Axial Spondyloarthritis

Interventions

BIOLOGICAL

Adalimumab

40 mg every other week up to Week 12

BIOLOGICAL

Placebo

Placebo every other week up to Week 12

BIOLOGICAL

Open-label Adalimumab

40 mg every other week, Week 12 through Week 156

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Aileen L Pangan, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-02-28
Completion
2013-08-31

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939003 on ClinicalTrials.gov